Literature DB >> 18039526

Structure and function of human plasma carboxypeptidase N, the anaphylatoxin inactivator.

Randal A Skidgel1, Ervin G Erdös.   

Abstract

Human carboxypeptidase N (CPN) was discovered in the early 1960s as a plasma enzyme that inactivates bradykinin and was identified 8 years later as the major "anaphylatoxin inactivator" of blood. CPN plays an important role in protecting the body from excessive buildup of potentially deleterious peptides that normally act as local autocrine or paracrine hormones. This review summarizes the structure, enzymatic properties and function of this important human enzyme, including insights gained by the recent elucidation of the crystal structure of the CPN catalytic subunit and structural modeling of the non-catalytic regulatory 83 kDa subunit. We also discuss its physiological role in cleaving substrates such as kinins, anaphylatoxins, creatine kinase, plasminogen receptors, hemoglobin and stromal cell-derived factor-1alpha (SDF-1alpha).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18039526      PMCID: PMC2679228          DOI: 10.1016/j.intimp.2007.07.014

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  89 in total

Review 1.  Metallocarboxypeptidases and their protein inhibitors. Structure, function and biomedical properties.

Authors:  J Vendrell; E Querol; F X Avilés
Journal:  Biochim Biophys Acta       Date:  2000-03-07

2.  Crystal structure of avian carboxypeptidase D domain II: a prototype for the regulatory metallocarboxypeptidase subfamily.

Authors:  F X Gomis-Rüth; V Companys; Y Qian; L D Fricker; J Vendrell; F X Avilés; M Coll
Journal:  EMBO J       Date:  1999-11-01       Impact factor: 11.598

3.  Carboxypeptidase B.I. Purification of the zymogen and specificity of the enzyme.

Authors:  J E FOLK; J A GLADNER
Journal:  J Biol Chem       Date:  1958-03       Impact factor: 5.157

4.  Plasmin alters the activity and quaternary structure of human plasma carboxypeptidase N.

Authors:  Mercy O Quagraine; Fulong Tan; Hironori Tamei; Ervin G Erdös; Randal A Skidgel
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

5.  Human carboxypeptidase N: lysine carboxypeptidase.

Authors:  R A Skidgel
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

6.  Nature and time course of generation of isoforms of creatine kinase, MB fraction in vivo.

Authors:  N A Prager; T Suzuki; A S Jaffe; B E Sobel; D R Abendschein
Journal:  J Am Coll Cardiol       Date:  1992-08       Impact factor: 24.094

7.  Crystal structure of the human carboxypeptidase N (kininase I) catalytic domain.

Authors:  Cora Keil; Klaus Maskos; Manuel Than; J Todd Hoopes; Robert Huber; Fulong Tan; Peter A Deddish; Ervin G Erdös; Randal A Skidgel; Wolfram Bode
Journal:  J Mol Biol       Date:  2006-11-11       Impact factor: 5.469

8.  Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats.

Authors:  B Kobe; J Deisenhofer
Journal:  Nature       Date:  1993 Dec 23-30       Impact factor: 49.962

9.  Immunoreactive bradykinin and [des-Arg9]-bradykinin in low-renin essential hypertension--before and after treatment with enalapril (MK 421).

Authors:  C E Odya; F P Wilgis; J F Walker; S Oparil
Journal:  J Lab Clin Med       Date:  1983-11

10.  By-product analogues for bovine carboxypeptidase B.

Authors:  T J McKay; T H Plummer
Journal:  Biochemistry       Date:  1978-02-07       Impact factor: 3.162

View more
  25 in total

1.  Carboxypeptidase N-deficient mice present with polymorphic disease phenotypes on induction of experimental autoimmune encephalomyelitis.

Authors:  Xianzhen Hu; Rick A Wetsel; Theresa N Ramos; Stacey L Mueller-Ortiz; Trenton R Schoeb; Scott R Barnum
Journal:  Immunobiology       Date:  2013-08-23       Impact factor: 3.144

Review 2.  Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function.

Authors:  Ervin G Erdös; Fulong Tan; Randal A Skidgel
Journal:  Hypertension       Date:  2010-01-11       Impact factor: 10.190

Review 3.  Complement regulators and inhibitory proteins.

Authors:  Peter F Zipfel; Christine Skerka
Journal:  Nat Rev Immunol       Date:  2009-09-04       Impact factor: 53.106

Review 4.  The complement system: history, pathways, cascade and inhibitors.

Authors:  P N Nesargikar; B Spiller; R Chavez
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-06-13

5.  Deletion of carboxypeptidase N delays onset of experimental cerebral malaria.

Authors:  M M Darley; T N Ramos; R A Wetsel; S R Barnum
Journal:  Parasite Immunol       Date:  2012 Aug-Sep       Impact factor: 2.280

Review 6.  Deciphering the Intricate Roles of Radiation Therapy and Complement Activation in Cancer.

Authors:  Jacob Gadwa; Sana D Karam
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-07-03       Impact factor: 7.038

7.  Cross-talk between carboxypeptidase M and the kinin B1 receptor mediates a new mode of G protein-coupled receptor signaling.

Authors:  Xianming Zhang; Fulong Tan; Viktor Brovkovych; Yongkang Zhang; Randal A Skidgel
Journal:  J Biol Chem       Date:  2011-03-31       Impact factor: 5.157

8.  Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.

Authors:  James L M Ferrara; Andrew C Harris; Joel K Greenson; Thomas M Braun; Ernst Holler; Takanori Teshima; John E Levine; Sung W J Choi; Elisabeth Huber; Karin Landfried; Koichi Akashi; Mark Vander Lugt; Pavan Reddy; Alice Chin; Qing Zhang; Samir Hanash; Sophie Paczesny
Journal:  Blood       Date:  2011-10-06       Impact factor: 22.113

9.  Complement c5a generation by staphylococcal biofilms.

Authors:  Ashley E Satorius; Jacob Szafranski; Derek Pyne; Mahesh Ganesan; Michael J Solomon; Duane W Newton; David M Bortz; John G Younger
Journal:  Shock       Date:  2013-04       Impact factor: 3.454

10.  A structural and functional analysis of Nna1 in Purkinje cell degeneration (pcd) mice.

Authors:  Hui-Yuan Wu; Taiyu Wang; Leyi Li; Kristen Correia; James I Morgan
Journal:  FASEB J       Date:  2012-07-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.